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Purpose: The prevalence of "ocal allergic rhinitis" within individuals suffering from perennial
rhinitis remains uncertain, and patients usually are diagnosed with non-allergic rhinitis. The aim of
this study was to evaluate the prevalence of a potential "local allergic rhinitis" in subjects suffering
from non-allergic rhinitis in a non-selected group of young students.
Methods: 131 students (age 25.0  5.1 years) with a possible allergic rhinitis and 25 non-allergic
controls without rhinitis symptoms (age 22.0  2.0 years) were recruited by public postings. 97 of
131 students with rhinitis were tested positive (3 mm) to prick testing with 17 frequent allergens
at visit 1. Twenty-four 24 subjects with a house dust mite allergy, 21 subjects with a non-allergic
rhinitis, and 18 non-allergic controls were further investigated at visit 2. Blood samples were
taken, and nasal secretion was examined. In addition, all groups performed a nasal provocation
test with house dust mite (HDM).
Results: In serum and nasal secretion, total IgE and house dust mite specific IgE significantly
differed between HDM positive subjects and controls. However, no differences between non-
allergic subjects and control subjects were quantifiable. Neither a nasal provocation test nor a
nasal IgE to HDM allergens showed a measurable positive response in any of the non-allergic
rhinitis subjects as well as the healthy controls, whilst being positive in 13 subjects with HDM
allergy.
Conclusions: Nasal IgE is present in subjects with HDM allergy, but not in non-allergic rhinitis. In
the investigated non-selected population, exclusive local production of IgE is absent. By impli-
cation, therefore, our findings challenge the emerging concept of local allergic rhinitis.
Study identifier at ClinicalTrials.gov: NCT 02810535.
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Allergic rhinitis (AR), seasonal or perennial, is a
very common disease in the western world. The
prevalence ranges from approximately 15% as
related by physicians and as high as 30% by pa-
tients reports.1,2 Most patients suffer from rather
mild symptoms like sneezing, nasal pruritus, and
congestion. Hence, only half of the patients seek
medical treatment. The diagnosis of AR is based
on characteristic symptoms and evidence of
sensitization, measured either by skin prick tests
(SPT) or the presence of allergen-specific IgE
(sIgE) in serum most frequently to birch and grass
pollen, mold, house dust mites (HDM), or animal
dander.
Diagnosis and treatment of most patients with
AR in clinical practice is not considered a major
challenge for an experienced physician. However,
in some patients the applicable diagnosis is diffi-
cult when physicians are faced with patients
suffering from typical symptoms of AR without any
objectifiable sensitization. In accordance with na-
tional and international guidelines, the differential
diagnosis includes further forms of rhinitis that are
non-allergic in origin such as vasomotor rhinitis,
non-allergic rhinitis with eosinophilia-syndrome
(NARES), and recently local allergic rhinitis
(LAR).3–6
The discovery of nasal IgE defined as local
production of IgE antibodies in the nasal mucosa
has been widely reported. In 1947 Samter and
Becker recognized that nasal secretions of in-
dividuals allergic to ragweed could be used to
passively transfer a local reaction to previously
non-allergic individuals. Furthermore, in 1970
ragweed specific IgE was detected in the nasal
washings of ragweed allergic patients.7 In 1975
Huggins and Brostoff reported that in patients
with symptoms indicating a possible AR, but with
negative SPT, IgE antibodies to HDM could be
found in nasal secretions.8 Sennekamp et al
described a high conversion rate from negative
to positive skin tests in patients with LAR.9
The term “LAR” was first proposed and intro-
duced by Rondón et al.10 These authors described
nasal provocation tests (NPT) with HDM being
positive in 54% of patients with a diagnosis of
non-allergic rhinitis in their hands.11Furthermore, in a recent review on AR, the au-
thors stated that LAR requires further study, and
the measurement of allergen-specific IgE in nasal
fluid is restricted to research only.2 In line with this
statement, most allergy specialists and clinics do
not measure nasal IgE to detect LAR in routine
practice. Therefore, the diagnosis of LAR only
relies on a positive nasal provocation test in
everyday practice, which may show falsely
positive results when not performed carefully.12,13
Indeed, the prevalence of LAR has been shown
in 47%–62.5% of patients in patients suffering from
perennial non-allergic rhinitis (NAR).11,14 Similar
results were recently described by Bozek et al
whom described the prevalence of NAR as high
as 42% in a study cohort of 621 individuals.15
Demographical differences might be attributable
as a study group in China found a prevalence of
LAR in only 7.7% of patients in a cohort of 195
individuals whilst Ishida et al recently published
data suggesting a prevalence of LAR in 2 of 14
patients (14.3%) and HDM LAR in 5 of 21 (23.8%)
in a study of 50 highly selected Japanese
patients suffering from chronic rhinosinusitis.16,17
Contrary to these conclusions others found no
prevalence of nasal IgE in patients with non-
allergic rhinitis.18 Such discrepant data was
obtained in selected populations of subjects
suffering from rhinitis. However, the prevalence of
LAR in the general population is still unexplored,
and true prevalence of LAR remains still to be
established. The aim of this prospective study
was to evaluate the prevalence of LAR in an
unselected population of young students
suffering from seasonal or perennial AR.MATERIALS AND METHODS
Subjects
Subjects were recruited by means of public
posting at the university campus and advertise-
ment on social media platforms. As a result, many
students of the Goethe University Frankfurt am
Main participated in the trial. The study was per-
formed in accordance with the declarations of
Good Clinical Practice (GCP) and registered by
ClinicalTrials.gov (NCT 02810535).
The population consisted of 131 (91 female and
40 male) subjects with symptoms of seasonal or
Fig. 1 Study flow chart and subject groups. Fig. 1. Study flow chart and subject groups. AR (allergic rhinitis); HDM (house dust mite); SAR
(seasonal allergic rhinitis); NAR (non-allergic rhinitis)
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healthy controls. Exclusion criteria were age <18
years, acute infections 4 weeks before study in-
clusion, severe diseases such as cystic fibrosis or
malignant diseases, present pregnancy or lacta-
tion, participation in another clinical trial within 30
days, documented alcohol and/or drug abuse, or
incapability to perform the study procedures.
Furthermore, we excluded all subjects with previ-
ous allergen immunotherapy against HDM from
the study. Immunotherapy against other perennial
allergens was not considered an exclusion crite-
rion since we did not expect any influence on the
study.Study design
Our study was a prospective, exploratory clinical
study specifically designed to investigate the
presence of local IgE in the nasal mucosa of sub-
jects with AR to HDM allergens (AR þ HDM), NAR
and healthy controls. The study comprised 2 visits,1 screening visit, and 1 visit for determination of
serum IgE, nasal IgE, and NPT.
A total of 156 subjects underwent visit 1, which
consisted of a physical examination, a health
questionnaire, lung function testing, and SPT.
68 participants were invited to a second visit
according to their clinical symptoms (perennial
rhinitis) and the results of the SPT (see Fig. 1).
During the second visit, nasal secretion and
blood samples were taken and a NPT with HDM
was performed.Health and activity questionnaire
The subjects were asked to fill out a question-
naire that had been taken, adjusted, and modified
from the International Study of Asthma and Al-
lergies in Childhood (ISAAC) questionnaire (sup-
plementary material) in order to meet our study
design. It included questions on the employment
situation, asked for other kinds of diseases and
symptoms perennial or during pollen season, and
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wheezing and dry cough. Additionally, the ques-
tionnaire evaluated medical conditions related to
allergic symptoms of the nose and eyes and
measured the intake of medication such as anti-
histamines, rapid-acting beta-2 agonists, nasal
drops, eye drops, and topical cortisone. The sub-
jects had to rank the frequency of the intake of
their before mentioned medications on a scale
from 0 to 6. Whereas 0 showed no intake and 6
showed consumption over 16 times (maximum
sum score was 30). Regarding nasal symptoms, the
subjects had to assess the severity of the symp-
toms "blocked nose", "runny nose", "sneezing" and
"itchy nose’ on a scale from 0 (¼ none) to 6
(¼severe) (maximum sum score was 24).
Skin prick test
A SPT using 17 standard allergens (birch pollen,
alder pollen, hazelnut pollen, ash tree pollen, grass
pollen, rye pollen, ragweed pollen, mugwort pol-
len, plantain, Dermatophagoides farinae, Derma-
tophagoides pteronyssinus, Alternaria alternata,
Aspergillus fumigatus, Cladosporium herbarum,
cat, and horse) (Allergopharma, Merck, Reinbek,
Germany) was performed at visit 1 according to
international standard.6 The mean of the largest
diameter of the wheal and its perpendicular
diameter was recorded as the response. A
response of at least 3 mm and a negative saline
control as well as a response to histamine as
positive control was considered as positive
regarding sensitization to the tested allergen.
Pulmonary function test
Baseline pulmonary function tests were per-
formed using the plethysmograph JAEGER Mas-
terScreen Body (CareFusion Germany 234 GmbH,
Hoechberg, Germany). The following parameters
were recorded: forced vital capacity (FVC), forced
expiratory volume in one second (FEV1), and
FEV1%FVC ratio (FEV1%/FVC).
Collection of nasal secretion
After inspection of the nasal cavity with a nasal
speculum, a cotton swab was placed underneath
the lower turbinate and left there for at least
15 min.19 For that, cotton swabs with a diameter of1.0 cm were used (M þ W Select cotton rolls with
pulp, Müller & Weygandt GmbH, Büdingen,
Germany). After obtaining the nasal secretion, the
swabs were sealed in a Salivette (Sarstedt AG &
Co. KG, Nuembrecht, Germany) and centrifuged
at 3000 revolutions for 10 min. Then, the
centrifuged secretion was transferred into
Eppendorf tubes and frozen at 80 C until
further analysis.Nasal provocation test
The NPT was performed according to our lab-
oratory's standard as recently described in more
detail and interpreted in concordance with inter-
national standards.4,5,20,21 Before starting the
NPT, we made sure that no patient had used any
treatment for rhinitis before. After nasal secretion
collection, a NPT with HDM allergen was
performed.22 First, the lyophilised HDM allergen
Dermatophagoides farinae (Dpt. 708,
Allergopharma, Merck, Reinbek, Germany) was
dissolved in 5 mL of 0.9% saline, resulting in a
solution with a dosage of 5000 AU/mL. The
solution was transferred in a pump dosing spray
of which one spray-puff equates to 0.04–0.05 mL
with a dosage of 400 AU. Whereas the negative
control was a physiological saline solution (0.9%)
with phenolic preservation. The negative control
was used to determine values prior to the provo-
cation itself. The reaction to the NPT was measured
using two different methods: Lebel symptom score
scale and measurement of peak nasal inspiratory
flow (PNIF).
To determine the nasal flow rate and to objectify
nasal obstruction the Inspiratory Flow Meter In-
Check Nasal (Clement Clarke International Ltd,
Essex, UK) was used. One measurement consisted
of 3 attempts whereof the highest value was
selected.
The Lebel symptom score scale recorded the
frequency of sneezing (0–3 points), the extent of
rhinorrhea (0–2 points), the severity of nasal
obstruction (0–3 points), and possible concomitant
itching of the nose, palate, ear, or eye (0–3 points),
as described.23
First, the baseline scores were obtained,
requiring a Lebel score <3 and a PNIF of at least
Volume 13, No. 6, June 2020 550 L/min. Then the negative control solution was
applied with one spray-puff into each nostril. After
10 min the Lebel and PNIF scores were recorded.
When a decrease of the PNIF from baseline score
was detected and either >20% or the Lebel score
had a value  3 the NPT was terminated due to an
unspecific reaction. The score evaluation was fol-
lowed by the application of the HDM allergen so-
lution, one spray-puff for each nostril. After another
10 min, the scores were again evaluated. The NPT
was considered to be positive if either the Lebel
score after HDM provocation was 6 or a decrease
of the PNIF from after saline to after HDM was
>40%.
A nasal spray rescue medication with xylome-
tazoline hydrochloride as main active substance
(Otriven 0.1%, GlakoSmithKline GmbH & Co. KG,
Munich, Germany) was offered to subjects with a
strong nasal reaction.Laboratory measurements
Coded blinded serum and nasal secretions on
dry ice were sent to the Upper Airways Research
Laboratory of the Ghent University for IgE de-
terminations. Serum and nasal secretions were
analyzed for total IgE and specific IgE to HDM
(D1 ¼ Dermatophagoides pteronyssinus) andControls
Subjects [number] n ¼ 18
Gender [number] f ¼ 15, m ¼
Age [years, mean  SD] 22.39  1.91
FVC [%pred, mean  SD] 99.63  10.3
FEV1 [%pred, mean  SD] 97.94  11.6
FEV1%/FVC [%, mean  SD] 85.41  6.77
HDM SPT positivity [%, mean  SD] 0  0




Serum sIgE-D1 [kUA/L, median and
range]
0.05 (0.05–0.3
Serum sIgE-D2 [kUA/L, median and
range]
0.05 (0.05–0.3
Table 1. Clinical characteristics. ***/****, P  0.001 compared to subjects with
controls and subjects with NAR(D2 ¼ Dermatophagoides farinae) by using the
UniCAP system (Thermo Fisher Scientific – Immu-
noDiagnostics, Groot-Bijgaarden, Belgium). Anal-
ysis was performed according to the
manufacturer's instructions.
Statistical analysis
The data were analyzed using Microsoft Excel
2016 for Mac (Microsoft Corporation, Redmond,
WA, USA), GraphPad Prism 7 for Mac OS X
(GraphPad Software, La Jolla, CA, USA), and SPSS
Version 19.0 (IBM, Chicago, Illinois, USA). All P-
values < 0.05 were considered to be statistically
significant. The parameters were tested for normal
distribution using the D'Agostino & Pearson
normality test. Normally distributed values are
indicated as mean value and standard deviation
(SD), whereas not normally distributed values are
indicated as median and range. The non-
parametric Kruskal-Wallis test and Mann-Whitney
U test were used for comparison between not
normally distributed values, whereas ANOVA was
used for comparison between normally distributed
values. To compare nominal data, the Fisher-
Freeman-Halton's exact test was used. Correlations
between the PNIF values, the Lebel score, and the
nasal specific IgE were calculated using the
Spearman's rank correlation test.AR þ HDM NAR
n ¼ 24 n ¼ 21
3 f ¼ 16, m ¼ 8 f ¼ 17, m ¼ 4
23.92  3.99 24.19  3.34
8 101.45  10.99 98.24  10.34
6 95.77  11.92 96.62  10.60
81.91  8.88 85.08  7.78





2) 27.99 (0.11–311.48) **** 0.05 (0.05–1.47)
6) 33.22 (1.47–447.80) **** 0.05 (0.05–1.59)
NAR and P  0.0001 compared to controls; ****, P  0.0001 compared with
Controls AR þ HDM NAR
Duration of perennial symptoms [years, median and range] - 9 (2–25) 5 (0–20)








Antihistamines 0 (0%) 9 (50.00%)
***/n.s.
2 (13.33%)n.s.
Eye drops 0 (0%) 4 (22.22%) 3 (20.00%)
Nasal drops 1
(5.56%)
9 (50.00%) 7 (46.67%)
Rapid-acting b2-agonists 0 (0%) 3 (16.67%) 1 (6.67%)
Topical Cortisone use 0 (0%) 2 (11.11%) 1 (6.67%)
Table 2. Symptoms and medication intake. For the separate drugs, the number of subjects using them for their allergic complaints during the last year,
are listed. **** - P  0.0001 compared to controls; ***/n.s.- P  0.001 compared to controls/AR þ HDM compared to NAR: not significant, n.s. - not significant
when compared to controls
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Subjects characteristics
We screened 156 subjects in total (82.7% stu-
dents), 131 subjects with reported seasonal or
perennial rhinitis, and 25 healthy controls. Five
healthy controls without rhinitis symptoms where
excluded due to a positive SPT against HDM, and 2
further subjects were excluded due to reaction to
NaCl (negative control) in the SPT. Of the 35 sub-
jects with perennial nasal symptoms and positive
SPT against HDM (ARþ HDM), 26 agreed to attend
the follow up visit. Twenty-two of 33 NAR subjects,
22 and 20 of 25 healthy controls agreed to attend
the follow up visit, resulting in 68 subjects willing
to participate in visit 2. The 68 subjects were then
invited to a second visit. Five of the 68 invited
subjects were excluded due to different reasons:
new diagnosed leukemia (n ¼ 1), withdrawal of
consent (n ¼ 2), and the participation in other
studies (n ¼ 2), see Fig. 1. Twenty-four subjects
with AR þ HDM (age: 23.9  4.0), 21 subjects
with NAR (age: 24.2  3.3), and 18 healthy
control subjects with no allergic symptoms (age:
22.4  1.9) fulfilled the inclusion criteria.
As shown in Table 1, groups were age-matched
(ns) with a higher percentage of women in all
groups (66.7%–83.3%). Even though the percent-
age of women was higher, there was no significantdifference regarding the distribution of female and
male participants between the groups.
There was no difference regarding the FVC,
FEV1 and FEV1/FVC ratio between groups. Sub-
jects with AR þ HDM had higher levels of total and
specific IgE in serum than controls and subjects
with NAR (P < 0.0001).Clinical symptoms and medication
Duration of rhinitis, impairment by rhinitis
symptoms, nasal symptom scores, and medication
intake are shown in Table 2. Subjects with
AR þ HDM and subjects with NAR had a
significantly higher nasal sum score than controls
(P < 0.0001). The nasal sum score between
subjects with AR þ HDM and NAR (ns) did not
differ. As expected, the sum score regarding the
medication intake from subjects with AR þ HDM
(P  0.001) and NAR (P  0.05) differed
significantly from controls.
The severity of nasal symptoms (sneezing,
blocked-, runny- and itchy nose) is shown in Fig. 2.
As shown, severity of nasal symptoms of subjects
with AR þ HDM did not differ from NAR, but
significantly increased compared to controls.
Fig. 2 Severity of nasal symptoms. Fig. 2: Severity of nasal symptoms ‘blocked nose’ (A), ‘runny nose’ (B), ‘sneezing’ (C) and ‘itchy nose’ (D).
Sum scores were compared using the Kruskal-Wallis test. **** - P  0.0001; n.s. – no significant difference
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Of the 156 screened subjects, 104 (66%)
showed sensitization against one of the tested
antigens. Of the 131 subjects with rhinitis symp-
toms 97 participants, (74%) had a positive SPT. Of
these subjects, 8.25% (n ¼ 8/97) were mono-
sensitized whilst 91.75% (n ¼ 89/97) were sensi-
tized against more than 1 antigen.
The subgroup analysis showed positive SPT in
all of the AR þ HDM subjects. Within this group,
95.83% were sensitized against both species of
Dermatophagoides. Of AR þ HDM subjects,
83.33% further showed sensitization against other
antigens. None of the controls was positive in SPT,
but 23.81% of subjects with NAR showed sensiti-
zation against seasonal allergens but not against
HDM, molds, or dander whilst having perennial
allergic symptoms. Of this subgroup, 1 patient
showed a positive reaction to grass pollen (8 mm)
whilst another individual tested positively against
ash pollen (7 mm) in the SPT. All other individualsof the NAR group showed minor reactions just
above threshold ranging between 3 mm and 4 mm
without any clinical significance. The control group
showed no positivity in SPT against HDM or any of
the further tested allergens.Local IgE in nasal secretion
In 17 of 18 (94.4%) controls, 21 of 24 (87.5%)
subjects with AR þ HDM and 17 of 21 subjects with
NAR (80.9%) we were able to obtain a quantita-
tively sufficient amount of nasal secretion which
was further analyzed for IgE. As shown in Fig. 3,
there were significant differences (P < 0.0001) in
total IgE and specific IgE to D1 and D2 between
groups. There were no significant differences
regarding the total IgE and specific IgE between
controls and subjects with NAR. None of the
controls or the subjects with NAR had specific
IgE to HDM expressed in nasal secretions as
shown in Fig. 3.
Controls
Lebel after HDM  6 0/17
PNIF decrease after HDM > 40% 0/17
Lebel  6 AND PNIF decrease > 40% 0/17
Lebel  6 OR PNIF decrease > 40% 0/17
Lebel score 0 (0–2)
PNIF Reduction [L/min, median and
range]
0 (þ20–30
PNIF Reduction [%, median and range] 0 (þ20.00
15.79)
Table 3. Results of nasal provocation test with HDM allergen HDM (house
to controls, P  0.001 compared to NAR; n.s.- no significant difference compare
Fig. 3 Comparison of total IgE and specific IgE to D1 and D2 in
nasal secretion between groups. Fig. 3. Comparison of total IgE (in
kilo international units (IU) of IgE per liter (kU/L) and sIgE (in kilo)
international units (IU) of allergenspecific antibody per liter (kUA/L)
to D1 (Dermatophagoides pteronyssinus) and D2
(Dermatophagoides farinae) in nasal secretion between groups, in
log10. Kruskal-Wallis test results regarding the P-values are shown
in the graphs
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The NPT was performed in all groups. Three
subjects with AR þ HDM and 1 subject with NAR
did not start the NPT due to a Lebel baseline score
3 or a PNIF less than 50 L/min. After provocation
with saline control solution, 7 subjects with
AR þ HDM, 1 subject with NAR, and 1 control were
excluded due to an unspecific reaction with either
a decrease of >20% regarding the PNIF or a Lebel
score 3. After provocation with HDM, 13 subjects
with AR þ HDM either had a Lebel score 6 points
or a decrease in PNIF >40% which was considered
to be a positive reaction. None of the controls and
the subjects with NAR had a positive reaction to
provocation with HDM as shown in Table 3. The
PNIF decrease in percentage also differed
significantly between controls and subjects with
AR þ HDM (P < 0.0001) and between subjects
with AR þ HDM and NAR (P ¼ 0.001) but not
between controls and NAR subjects (ns) (Table 3).
Test for correlations between NPT and nasal
specific IgE
We found significant correlations between the
specific IgE of D1 (r ¼ - 0.59, P  0.01) and D2
(r ¼ - 0.65, P  0.01) measured in nasal secretion
and the reaction to provocation with HDM
measured via PNIF decrease. Thus, higher sIgE D1
and D2 values were related to a higher decrease of
the PNIF after HDM provocation. The values for
specific IgE, D1 and D2, also correlated signifi-
cantly with the Lebel symptom score, for D1





7.5 (4–10) 2 (0–5)





dust mite), PNIF (peak nasal inspiratory flow). ****/*** - P  0.0001 compared
d to controls
Volume 13, No. 6, June 2020 9The higher the sIgE in nasal secretion, the higher
the evaluated Lebel symptom score after HDM
provocation.
All controls and subjects with NAR with a
negative Radioallergosorbent Test (RAST) (<0.35
kUA/L) for D1 and D2 in nasal secretion (n ¼ 28)
also had a negative Lebel score and PNIF after
HDM provocation.DISCUSSION
In our study we were able to investigate a col-
lective of non-selected adult individuals suffering
from NAR and compare the findings to subjects
suffering from AR þ HDM as well as healthy con-
trols. Since all subjects were recruited by public
posting, no selection bias was to be expected,
resulting in a better characterization of the preva-
lence of LAR in the field of chronic rhinitis.
In concordance with findings of previous in-
vestigations, the nasal sum score between subjects
with AR þ HDM and NAR did not differ signifi-
cantly.11,24 As expected, total and sIgE was
significantly elevated in the serum of subjects
with AR þ HDM. In addition, we were able to
detect significantly elevated levels of total IgE
and sIgE to HDM in nasal fluid of subjects with
AR þ HDM demonstrating that our technique of
local IgE measurement was appropriate. In
contrast, none of the subjects suffering from NAR
showed elevated levels of total IgE and sIgE to
HDM in the nasal fluid. In keeping with these
findings none of our subjects with NAR had a
positive reaction to NPT with HDM.11 Since we
were able to detect elevated levels of IgE and
sIgE in the AR þ HDM group, attribution of the
negative test results to methodological errors is
highly unlikely.
Our findings on sIgE are in line with the results
obtained by Becker et al, who analyzed nasal
secretion of subjects with NARES using a state of
the art allergen chip.18 Of the 19 subjects included
in their study, none showed presence of LAR in the
immunochip-analysis. However, these findings and
our results are contrary to results published by
others.8,11 These discrepancies are difficult to
explain. Rondón et al were able to detect nasal
specific IgE to HDM in a substantial percentageof subjects suffering from perennial NAR using
nasal lavage.11
One could speculate that the presence of very
low specific IgE levels in nasal secretion could lead
to false negative results in the NAR group due to a
lack of sensitivity regarding the measuring
method. However, the test was carried out in one
of the world's most renowned allergological lab-
oratories and that measurable and specific IgE was
detected by other working groups in measurable
quantities in NAR subjects.11,25 Furthermore, as
nasal lavage actually dilutes the secretions
further, it makes a specific measurement even
more unlikely. In addition, a pre-selection of sub-
jects regarding perennial and non-perennial NAR
might be also relevant.
By implication, therefore, our findings challenge
the concept of a LAR which has emerged in the
past years and is by some authors believed to be a
pathological entity on its own,26 whilst others
stated that LAR might be an early form of NAR
developing into AR or other kinds atopic
diseases like Samter Widal triad.27–29 Recently a
long term follow up study of 176 patients with
LAR and 115 healthy controls was published,
describing that LAR is a distinct clinical entity
with a low rate of development to systemic
atopy.26
As we were unable to obtain either local sIgE in
nasal fluid nor any positive results in the NPT, the
prevalence of LAR in the field of NAR has to be
much lower in the investigated, non-selected
population then previously reported.14,24 These
discrepancies maybe related in part to
demographic and genetic differences or
technical reasons. Poor quality of SPT solution
might also be attributable to negative SPT results
and positive nasal IgE. However, most studies
measured serum IgE to verify or dismiss systemic
atopy. Of subjects with NAR, 23.81% showed
sensitization against seasonal allergens in the
SPT. In that regard one could argue that this
subgroup of patients is not a typical NAR
collective. However, all patients tested reported
perineal symptoms and tests were performed
outside the season for the specific pollen
allergen. As none of the NAR subjects showed
any sensitization to molds or dander attributing
the findings to other allergens seems unlikely.
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detection. Therefore, attribution of the high
prevalence of local sIgE to the used collection
technique seems unlikely, as the dilution effect of
nasal lavage has been shown to alter sensitivity
compared to obtaining nasal fluid straight from
the nasal cavity.30–32
In contrast to other studies, our population was
not highly selected by an otorhinolaryngology
center. Therefore, we truly believe that our study is
representative of the normal population in Ger-
many. Due to the public posting, our study group
consisted of individuals with nasal symptoms. As
study recruitment was done in a metropolitan area
of Frankfurt, the subjects recruited had a diverse
geographical and ethnical background. In addi-
tion, the subjects' age and health profile are similar
to individuals investigated by other working
groups.11,18
Biopsies from nasal mucosa would maybe help
to further investigate the prevalence of nasal IgE
and would give a more detailed insight into the
immunopathological changes present in NAR as
previously described.33,34 As obtaining biopsies
are invasive, new techniques for immunological
analysis present an appealing concept.30,35CONCLUSION
Nasal IgE is present in a substantial amount in
subjects with AR þ HDM allergy, but not in NAR. In
a non-selected population with NAR, exclusive
local production of IgE is absent. Therefore, our
findings challenge the emerging concept of LAR.
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